Instanosis Inc.

Instanosis Inc. develops high-sensitivity diagnostic technology for rapid drug detection in clinical, harm reduction, forensic, and law enforcement applications. The company manufactures FDA-cleared, CLIA-waived dipstick and test strip products for detecting fentanyl, xylazine, and nitazene in human urine and other biological samples. Products are reported to be 25 times more sensitive than competitor alternatives and have been validated in clinical settings with over 1,000 urine samples. Instanosis supplies hospital-grade drug detection systems for healthcare facilities, rapid response kits for outreach and shelters, field testing solutions for forensic teams, and distributes through GPOs and medical distributors. The company is NIH-funded and manufactures all products in the United States. Their diagnostic portfolio includes lateral flow assays and monoclonal antibody reagents (anti-fentanyl Clone H16) for ELISA and immunoassay development. The company targets clinical trial support, disease diagnosis and monitoring, overdose response, and harm reduction programs.